Evidence map›Paper›PMID 41401031›Full record

ArticleLeukemia & lymphoma2026

NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia.

John R Sanchez, Chaomei Liu, Vishakha Pawar, Yanqing Huang, Daisy Diaz-Rohena, Jyotsana Singh, Priya Koppikar, Tzung-Huei Lai, Lisa St John, Vinay Puduvalli and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia & lymphoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

John R SanchezDepartment of Hematopoietic Biology and Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Chaomei LiuDepartment of Hematopoietic Biology and Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Vishakha PawarDepartment of Hematopoietic Biology and Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Yanqing HuangEvolution of Cancer, Leukemia, and Immunity Post Stem Cell Transplant (ECLIPSE), The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Daisy Diaz-RohenaDepartment of Hematopoietic Biology and Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Jyotsana SinghDepartment of Hematopoietic Biology and Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Priya KoppikarEvolution of Cancer, Leukemia, and Immunity Post Stem Cell Transplant (ECLIPSE), The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Tzung-Huei LaiDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Lisa St JohnDepartment of Hematopoietic Biology and Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Vinay PuduvalliDepartment of Neuro-oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Jeffrey MolldremDepartment of Hematopoietic Biology and Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Palaniraja ThandapaniDepartment of Hematopoietic Biology and Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Nitin JainDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-0114-8384
Rosa LapalombellaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Deepa SampathDepartment of Hematopoietic Biology and Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Funding

Characterization of Onalespib, A novel long acting Hsp90 inhibitor, as a chemo and radiosensitizer in Adults with Newly Diagnosed GlioblastomaR01CA235673 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PUDUVALLI, VINAY K, SAMPATH, DEEPA · 2019 to 2024
$2.9M
Targeting NAMPT in Acute Myeloid LeukemiaR01CA223165 · NCI · OHIO STATE UNIVERSITY · PI LAPALOMBELLA, ROSA, MIMS, ALICE SCOTT · 2018 to 2022
$2.3M
NCI NIH HHS R01 CA223165NCI NIH HHS R01 CA235673
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) cells depend on nicotinamide adenine dinucleotide (NAD

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicCytokinesLeukemia, Myeloid, AcuteNicotinamide PhosphoribosyltransferaseSulfonamidesAcrylamidesApoptosisCell Line, TumorDrug SynergismHumansPiperidinesProto-Oncogene Proteins c-bcl-2AcrylamidesBridged Bicyclo Compounds, HeterocyclicCytokinesN-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamideNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, humanPiperidinesProto-Oncogene Proteins c-bcl-2SulfonamidesvenetoclaxAMLBCL-2 dependencyDNA repair impairmentKPT-9274metabolic vulnerabilityNAMPT inhibition

Identifiers

PMID41401031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.